keyword
MENU ▼
Read by QxMD icon Read
search

Allogenic transplantation

keyword
https://www.readbyqxmd.com/read/29037020/factors-associated-with-pulmonary-toxicity-after-myeloablative-conditioning-using-fractionated-total-body-irradiation
#1
Hwa Kyung Byun, Hong In Yoon, Jaeho Cho, Hyun Ju Kim, Yoo Hong Min, Chuhl Joo Lyu, June-Won Cheong, Jin Seok Kim, Hyo Sun Kim, Soo-Jeong Kim, Andrew Jihoon Yang, Byung Min Lee, Won Hee Lee, Joongyo Lee, Ki Jung Ahn, Chang-Ok Suh
PURPOSE: Pulmonary toxicities, including infectious pneumonia (IP) and idiopathic pneumonia syndrome (IPS), are serious side effects of total body irradiation (TBI) used for myeloablative conditioning. This study aimed to evaluate clinical factors associated with IP and IPS following TBI. MATERIALS AND METHODS: Fifty-eight patients with hematologic malignancies who underwent TBI before allogeneic hematopoietic stem cell transplantation between 2005 and 2014 were reviewed...
September 2017: Radiation Oncology Journal
https://www.readbyqxmd.com/read/29035589/the-activity-of-nintedanib-in-an-animal-model-of-allogenic-left-lung-transplantation-resembling-aspects-of-allograft-rejection
#2
Marietta von Suesskind-Schwendi, Elke Boxhammer, Stephan W Hirt, Stephan Schreml, Christof Schmid, Lutz Wollin, Karla Lehle
AIM OF THE STUDY: The prevention and treatment of chronic lung allograft dysfunction (CLAD) after lung transplantation (LTx) remain unsatisfactory. Growth factors may play an important role in the development of CLAD. This study evaluated the effects of nintedanib, a receptor tyrosine kinase inhibitor, in the treatment of CLAD after experimental LTx. MATERIALS AND METHODS: A rat model of left lung allo-transplantation (Fisher 344 to Wistar Kyoto) was used to evaluate the effect of nintedanib (50 mg/kg per day) on the development of CLAD...
October 16, 2017: Experimental Lung Research
https://www.readbyqxmd.com/read/29035398/risks-factors-and-timing-of-genital-human-papillomavirus-hpv-infection-in-female-stem-cell-transplant-survivors-a-longitudinal-study
#3
D Shanis, P Anandi, C Grant, A Bachi, N Vyas, M A Merideth, P A Pophali, E Koklanaris, S Ito, B N Savani, A J Barrett, M Battiwalla, P Stratton
This longitudinal single-center study describes the timing and risk factors for genital human papillomavirus (HPV) disease in women after allogeneic hematopoietic cell transplantation (HCT). Between 1994 and 2014, 109 females underwent HCT of whom 82 surviving transplant for >1 year had regular, comprehensive genital tract assessment and treatment of HPV disease. The cumulative proportions of any genital HPV infection at 1, 3, 5, 10 and 20 years were 4.8%, 14.9%, 28.1%, 36.7% and 40.9%, respectively. Demographic, disease-related factors, chronic GvHD (cGvHD) and its treatment were analyzed for their association with persistent, multifocal or severe genital HPV disease...
October 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29035392/long-term-outcome-of-mixed-chimerism-after-stem-cell-transplantation-for-thalassemia-major-conditioned-with-busulfan-and-cyclophosphamide
#4
N A Fouzia, E S Edison, K M Lakshmi, A Korula, S R Velayudhan, P Balasubramanian, A Abraham, A Viswabandya, B George, V Mathews, A Srivastava
Mixed chimerism (MC) occurs frequently after allogeneic hematopoietic stem cell transplantation (HSCT) for thalassemia major (TM) and may be associated with rejection. We report the outcome of MC in 132 TM patients conditioned with Busulphan/Cyclophosphamide, who had successful engraftment and had ⩾1 year follow-up. Chimerism was first assessed at day +28, then every 3-9 months or more frequently if there was MC. If rejection was suspected, immunosuppression was stopped and donor-lymphocyte infusion (DLI) was given if there was no response...
October 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29033451/dasatinib-and-azacitidine-followed-by-haploidentical-stem-cell-transplant-for-chronic-myeloid-leukemia-with-evolving-myelodysplasia-a-case-report-and-review-of-treatment-options
#5
Fabian Lang, Lydia Wunderle, Heike Pfeifer, Susanne Schnittger, Gesine Bug, Oliver G Ottmann
BACKGROUND CML presenting with a variant Philadelphia translocation, atypical BCR-ABL transcript, additional chromosomal aberrations, and evolving MDS is uncommon and therapeutically challenging. The prognostic significance of these genetic findings is uncertain, even as singular aberrations, with nearly no data on management and outcome when they coexist. MDS evolving during the course of CML may be either treatment-associated or an independently coexisting disease, and is generally considered to have an inferior prognosis...
October 16, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29033080/reconstitution-of-th17-tc17-and-treg-cells-after-paediatric-haematopoietic-stem-cell-transplantation-impact-of-interleukin-7
#6
Katrine Kielsen, Lars P Ryder, David Lennox-Hvenekilde, Monika Gad, Claus H Nielsen, Carsten Heilmann, Marianne Ifversen, Anders Elm Pedersen, Klaus Müller
Successful reconstitution of T lymphocytes after allogeneic haematopoietic stem cell transplantation (HSCT) is needed to establish the graft-versus-leukaemia effect and an effective anti-microbial defense, but the ratio between functionally different T-cell subsets needs to be balanced to avoid graft-versus-host disease (GVHD). IL-7 is essential for T-cell generation in the thymus and peripheral T-cell homeostasis. High IL-7 levels have been associated with impaired T-cell reconstitution, increased risk of acute GVHD and treatment-related mortality, but the underlying cellular mechanisms behind these associations have not been investigated previously...
October 9, 2017: Immunobiology
https://www.readbyqxmd.com/read/29032736/coccidioidomycosis-immunoglobulin-deficiency-safety-challenges-with-car-t-cells-therapy-for-relapsed-lymphoma
#7
Umar Zahid, Al-Aman Shaukat, Nida Hassan, Faiz Anwer
Treatment of patients with relapsed or refractory lymphoma may require allogenic hematopoietic stem cell transplant (HSCT), but treatment of post-transplant relapse disease remains very challenging. Donor lymphocyte infusion and blinatumomab have been used with limited success for the treatment of relapse. Initial data on donor-derived CAR T cells has shown this modality to be safe and highly effective in various hematological malignancies. We present a case of a patient with highly refractory, transformed follicular lymphoma who failed both autologous and allogenic HSCT...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032733/car-t-cells-and-allogeneic-hematopoietic-stem-cell-transplantation-for-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia
#8
Jun Liu, Xi Zhang, Jiang F Zhong, Cheng Zhang
Relapsed/refractory acute lymphoblastic leukemia (ALL) has a low remission rate after chemotherapy, a high relapse rate and poor long-term survival even when allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed. Chimeric antigen receptors redirected T cells (CAR-T cells) can enhance disease remission with a favorable outcome for relapsed/refractory ALL, though some cases quickly relapsed after CAR-T cell treatment. Thus, treatment with CAR-T cells followed by allo-HSCT may be the best way to treat relapsed/refractory ALL...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032731/cytogenetic-risk-stratification-may-predict-allogeneic-hematopoietic-stem-cell-transplantation-outcomes-for-chronic-myelomonocytic-leukemia
#9
Kenji Motohashi, Shin Fujisawa, Noriko Doki, Takeshi Kobayashi, Takehiko Mori, Kensuke Usuki, Masatsugu Tanaka, Shinichiro Fujiwara, Shinichi Kako, Yasuyuki Aoyama, Masahiro Onoda, Shingo Yano, Moritaka Gotoh, Heiwa Kanamori, Satoshi Takahashi, Shinichiro Okamoto
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34...
October 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29032276/reversal-of-low-donor-chimerism-following-hematopoietic-cell-transplantation-using-pentostatin-and-donor-lymphocyte-infusion-a-prospective-phase-ii-multicenter-trial
#10
Merav Bar, Mary E D Flowers, Barry E Storer, Thomas R Chauncey, Michael A Pulsipher, Monica S Thakar, Wolfgang Bethge, Rainer Storb, David G Maloney, Brenda M Sandmaier
In a multicenter prospective Phase II study, we evaluated the safety and efficacy of pentostatin followed by donor lymphocyte infusion (DLI) in patients with low donor T-cell chimerism after allogeneic hematopoietic cell transplantation (HCT). Thirty-six patients with low donor blood CD3 chimerism were enrolled in this study. Thirty-five patients received a total of 41 DLIs following a dose of pentostatin, and one patient received pentostatin only. Median donor CD3 chimerism prompting the initiation of pentostatin/DLI was 28 (5 to 47)%...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032274/assessment-of-impact-of-human-leukocyte-antigen-hla-type-on-outcomes-of-allogeneic-hematopoietic-stem-cell-transplant-for-chronic-lymphocytic-leukemia-cll
#11
Brian T Hill, Kwang Woo Ahn, Zhen-Huan Hu, Mahmoud Aljurf, Amer Beitinjaneh, Jean-Yves Cahn, Jan Cerny, Mohamed A Kharfan-Dabaja, Siddhartha Ganguly, Nilanjan Ghosh, Michael R Grunwald, Yoshihiro Inamoto, Tamila Kindwall-Keller, Taiga Nishihori, Richard F Olsson, Ayman Saad, Matthew Seftel, Sachiko Seo, Jeffrey Szer, Martin Tallman, Celalettin Ustun, Peter H Wiernik, Richard T Maziarz, Matt Kalaycio, Edwin Alyea, Uday Popat, Ronald Sobecks, Wael Saber
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with many highly effective therapies. Chemorefractory disease, often characterized by deletion of chromosome 17p, has historically been associated with very poor outcomes, leading to the application of allogeneic hematopoietic stem cell transplant (allo-HCT) for medically fit patients. Although the use of allo-HCT has reduced since the introduction of novel targeted therapy for the treatment of CLL, there remains significant interest in understanding factors that may influence the efficacy of allo-HCT as it represents the only known curative treatment for CLL...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032273/torquetenovirus-dynamics-and-immune-marker-properties-in-patients-following-allogeneic-hematopoietic-stem-cell-transplantation-a-prospective-longitudinal-study
#12
Philipp Wohlfarth, Michael Leiner, Christian Schoergenhofer, Georg Hopfinger, Irene Goerzer, Elisabeth Puchhammer-Stoeckl, Werner Rabitsch
BACKGROUND: Torquetenovirus (TTV) has been proposed as a marker of immune function in patients receiving immunosuppression after solid organ transplantation. This study aimed to define TTV plasma dynamics and investigate clinical associations in patients following allogeneic hematopoietic stem cell transplantation (HSCT). METHODS: Single-center prospective longitudinal study involving 50 consecutive patients treated with HSCT between March 2015 and April 2016. TTV plasma DNA levels were measured with quantitative PCR on twelve consecutive timepoints during the first year following HSCT...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032272/fludarabine-and-busulfan-versus-fludarabine-cyclophosphamide-and-rituximab-as-reduced-intensity-conditioning-for-allogeneic-transplantation-in-follicular-lymphoma
#13
Narendranath Epperla, Kwang Woo Ahn, Philippe Armand, Samantha Jaglowski, Sairah Ahmed, Vaishalee P Kenkre, Bipin Savani, Madan Jagasia, Nirav N Shah, Timothy S Fenske, Ana Sureda, Sonali M Smith, Mehdi Hamadani
BACKGROUND: Large, multicenter studies comparing commonly used reduced-intensity conditioning (RIC) approaches in follicular lymphoma (FL) have not been performed. Using the CIBMTR database, we report the outcomes of two most commonly used RIC approaches, fludarabine and busulfan (Flu/Bu) vs. fludarabine, cyclophosphamide and rituximab (FCR) in FL patients. METHODS: We evaluated 200 FL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received RIC with either Flu/Bu (n=98) or FCR (n=102) during 2008-2014...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032269/second-hematopoietic-sct-for-thalassemia-major-improved-clinical-outcomes-with-a-treosulfan-based-conditioning-regimen
#14
Anu Korula, Nisham P N, Anup Devasia, Kavitha M Lakshmi, Aby Abraham, Eunice Sindhuvi, Biju George, Alok Srivastava, Vikram Mathews
Graft rejection (GR) following an allo-SCT occurs in 10-20% of patients with β thalassemia major (TM). There is limited data on the clinical profile and long term outcome of patients who have had a graft rejection. We undertook a retrospective analysis of patients who had a graft failure post allogeneic SCT for TM at our center. From October, 1991 to June 2016, 55/506 (11%) patients transplanted for TM had a graft failure. An additional 7 patients with graft failure following an allo-SCT done at other centers were referred to us for a second transplant...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032268/total-marrow-lymphoid-irradiation-fludarabine-melphalan-tfm-conditioning-for-allogeneic-hematopoietic-cell-transplantation-hct
#15
Lindsay G Jensen, Tracey Stiller, Jeffrey Y C Wong, Joycelynne Palmer, Anthony Stein, Joseph Rosenthal
BACKGROUND: Reduced intensity conditioning regimens (RIC) for hematopoietic stem cell transplantation (HCT) can reduce morbidity and mortality, but patients with advanced disease may require alternate approaches. In an initial report of RIC (Fludarabine (FLU) and Melphalan (MEL)) with total-marrow-lymphoid irradiation (TMLI) in HCT for advanced hematological malignancies in 33 patients, we found the addition of TMLI to RIC was feasible and safe. Here we report long-term outcomes for these patients...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032267/long-term-follow-up-of-a-donor-versus-no-donor-comparison-in-multiple-myeloma-patients-at-first-relapse-after-failing-autologous-transplantation
#16
Francesca Patriarca, Benedetto Bruno, Hermann Einsele, Francesco Spina, Luisa Giaccone, Vittorio Montefusco, Miriam Isola, Chiara Nozzoli, Andrea Nozza, Fortunato Morabito, Paolo Corradini, Renato Fanin
We report the long-term clinical outcomes of a retrospective multicentre study that enrolled 169 multiple myeloma (MM) patients at first relapse after failing autologous stem cell transplantation (SCT). After HLA-typing at relapse, 79 patients with a suitable donor, 72 (91%) of whom eventually underwent salvage allogeneic SCT, were compared with 90 patients without a donor who were treated with multiple lines of salvage treatment with bortezomib and/or immune-modulating agents. At a median follow-up of 30 months (range 2-180) for all patients and 110 months (range 38-180) for surviving patients, 7-year progression free survival (PFS) was 18% in the donor group and 0% in the no-donor group (hazard ratio [HR] 2...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032266/hypoalbuminemia-at-day-90-is-associated-with-inferior-non-relapse-mortality-and-overall-survival-in-allogeneic-hct-recipients-a-confirmatory-study
#17
Hemant S Murthy, Kyle Sheets, Ambuj Kumar, Taiga Nishihori, Alain Mina, Julio C Chavez, Ernesto Ayala, Teresa Field, John Mathews, Frederick Locke, Lia Perez, Brian C Betts, Farhad Khimani, Branco Miladinovic, Athanasios Tsalatsanis, Jose Leonel Ochoa-Bayona, Melissa Alsina, Hugo Fernandez, Joseph Pidala, Claudio Anasetti, Mohamed A Kharfan-Dabaja
Prognostic biomarkers in allogeneic hematopoietic cell transplantation are needed to improve risk assessment and help guide therapeutic and surveillance strategies to mitigate the risk of death from the procedure. We previously identified hypoalbuminemia at day +90 post-transplantation as an independent predictor of increased non-relapse mortality and inferior overall survival in patients with acute myelogenous leukemia and myelodysplastic syndrome who were treated with an allogeneic hematopoietic cell transplant...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032265/effect-of-antithymocyte-globulin-source-on-outcomes-of-hla-matched-siblings-allogeneic-hematopoietic-stem-cell-transplantation-for-patients-with-severe-aplastic-anemia
#18
Xin Chen, Jialin Wei, Yong Huang, Yi He, Donglin Yang, Rongli Zhang, Erlie Jiang, Qiaoling Ma, Weihua Zhai, Jianfeng Yao, Guixin Zhang, Sizhou Feng, Mingzhe Han
OBJECTIVE: To evaluate efficacy of porcine antithymocyte globulin (ATG) in HLA-matched siblings allogeneic hematopoietic stem cell transplantation (MSD-HSCT) for patients with severe aplastic anemia (SAA). METHODS: The clinical data of 113 SAA patients who received MSD-HSCT from January 2005 to November 2016 were analyzed retrospectively. Of these, 58 patients received rabbit ATG as a part of conditioning regimen (R-ATG group), while the other 55 patients received porcine ATG (P-ATG group)...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29031640/the-application-of-mesenchymal-stem-cells-to-treat-thermal-and-radiation-burns
#19
Kathleen Rodgers, Sachin S Jadhav
Mesenchymal stem cells (MSCs) have been developed for a number of indications due to their regenerative and anti-inflammatory phenotypes and their utility is enhanced by the fact that allogeneic transplant is feasible with this cell type. Animal studies and early human cases indicate this has the potential to be an exciting new therapy for treating chronic non-healing wounds such as diabetic ulcers, burns and cutaneous radiation burns. This review will focus on the use of MSCs to treat thermal and radiation burns...
October 11, 2017: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/29030302/mesenchymal-stem-cell-therapy-for-retro-corneal-membrane-a-clinical-challenge-in-full-thickness-transplantation-of-biosynthetic-corneal-equivalents
#20
Vijayalakshmi Rajendran, Magdalena Netuková, May Griffith, John V Forrester, Lucia Kuffová
Artificial corneas (keratoprostheses) and biosynthetic collagen-based corneal equivalents are surgical implants designed to ease the global burden of corneal blindness. However, keratoprostheses in many cases fail due to development of fibrous retro-corneal membranes (RCM). Fibrous membranes which develop in the anterior chamber after prosthesis implantation do so on a matrix of fibrin. This study investigated fibrin deposition and RCM formation after full-thickness collagen-based hydrogel implants and compared them with syngeneic and allogeneic corneal grafts in mice...
October 10, 2017: Acta Biomaterialia
keyword
keyword
41551
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"